MIRA:NSD-MIRA Pharmaceuticals, Inc. Common Stock (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 1.16

Change

-0.01 (-0.85)%

Market Cap

USD 0.02B

Volume

0.37M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.32 (+0.41%)

USD 245.10B
AMGN Amgen Inc

+3.03 (+0.91%)

USD 178.89B
SNY Sanofi ADR

+0.79 (+1.37%)

USD 143.70B
GILD Gilead Sciences Inc

+0.01 (+0.01%)

USD 103.10B
BIIB Biogen Inc

+3.85 (+1.95%)

USD 28.50B
GRFS Grifols SA ADR

+0.34 (+3.89%)

USD 7.16B
AMRN Amarin Corporation PLC

N/A

USD 0.25B
SCLX Scilex Holding Company

+0.02 (+1.98%)

N/A
SCLXW Scilex Holding Company

-0.01 (-3.30%)

N/A

ETFs Containing MIRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.48% 70% C- 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.48% 70% C- 65% D
Trailing 12 Months  
Capital Gain -74.16% 10% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.16% 10% F 9% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.11% 56% F 29% F
Dividend Return -7.11% 56% F 28% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.06% 56% F 75% C
Risk Adjusted Return -33.78% 56% F 23% F
Market Capitalization 0.02B 13% F 17% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.